Ardaman Shergill, MD, University of Chicago, Chicago, IL, discusses developments in predicative biomarkers for rectal cancer. Existing biomarkers include DNA mismatch repair deficient (dMMR) and high microsatellite instability (MSI-H), and studies assessing cabozantinib with durvalumab, and pembrolizumab with lenvatinib will hopefully elucidate novel biomarkers. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.